News & Updates
Filter by Specialty:
Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
Adding dalpiciclib to an aromatase inhibitor (AI) significantly improves progression-free survival (PFS) vs an AI alone in first-line (1L) treatment of hormone receptor (HR)–positive, HER2-negative advanced breast cancer regardless of patients’ menopausal status, a phase III trial in 42 hospitals in China has shown.
Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
05 Jul 2023
Focal therapy an effective option for older, comorbid prostate cancer patients
Focal ablative therapy may be used as an alternative treatment for older or comorbid patients with prostate cancer who are not fit or willing to undergo radical treatment, suggests a study.
Focal therapy an effective option for older, comorbid prostate cancer patients
02 Jul 2023
Breast cancer deaths highest within 5 years from diagnosis, decrease afterwards
The risk of mortality for women with early invasive breast cancer is highest during the 5 years after diagnosis, according to a study. Deaths from breast cancer will continue beyond this point, but such risk tends to decrease during each subsequent 5-year period.
Breast cancer deaths highest within 5 years from diagnosis, decrease afterwards
27 Jun 2023
Sacituzumab govitecan proven safe, effective in metastatic breast cancer
Treatment with sacituzumab govitecan (SG) demonstrates clinically meaningful overall survival (OS) over single-agent chemotherapy in patients with pretreated, endocrine-resistant, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), as confirmed by the final OS analysis from the TROPiCS-02 study, presented at ASCO 2023.